L. Leopold

560 total citations
27 papers, 445 citations indexed

About

L. Leopold is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, L. Leopold has authored 27 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in L. Leopold's work include Cancer Treatment and Pharmacology (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Prostate Cancer Treatment and Research (6 papers). L. Leopold is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Prostate Cancer Treatment and Research (6 papers). L. Leopold collaborates with scholars based in United States, Israel and Germany. L. Leopold's co-authors include Yossi Shavit, Jon Holmlund, William L. Berry, J. R. Caton, Guru Sonpavde, Janet Maleski, Petr Karlov, Matt D. Galsky, В. Б. Матвеев and Thomas E. Hutson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

L. Leopold

26 papers receiving 434 citations

Peers

Countries citing papers authored by L. Leopold

Since Specialization

Citations

This map shows the geographic impact of L. Leopold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Leopold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Leopold more than expected).

Fields of papers citing papers by L. Leopold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Leopold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Leopold. The network helps show where L. Leopold may publish in the future.

Co-authorship network of co-authors of L. Leopold

This figure shows the co-authorship network connecting the top 25 collaborators of L. Leopold. A scholar is included among the top collaborators of L. Leopold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Leopold. L. Leopold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer 2018 ·Annals of Oncology ·Oliver Dorigo, Amit M. Oza, János L. Tanyi, James Strauss, Tanja Pejović, Sharad Ghamande, Prafull Ghatage, Jeannine Villella, (unknown), Lisa D. MacDonald, (unknown), Genevieve Weir, (unknown), Marianne M. Stanford, Robert Newton, L. Leopold, (unknown)	1
2	Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037 2016 ·Annals of Oncology ·Tara C. Gangadhar, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Anthony J. Olszanski, Jason J. Luke, Ani Sarkis Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, (unknown), L. Leopold, Thomas F. Gajewski	47
3	511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma 2015 ·European Journal of Cancer ·Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Gangadhar, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Peter D. Boasberg, Yufan Zhao, Robert U. Newton, Jessica Bowman, Janet Maleski, L. Leopold, Jeffrey S. Weber	28
4	Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial 2014 ·Annals of Oncology ·H. Hurwitz, Nikhil Uppal, (unknown), J. C. Bendell, (unknown), (unknown), John Nemunaitis, Philip J. Stella, J. Marc Pipas, Zev A. Wainberg, Robert Manges, William M. Garrett, Deborah Hunter, Jason Clark, L. Leopold, Richard Levy, V. Sandor	2
5	76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas 2012 ·European Journal of Cancer ·Herbert I. Hurwitz, Henry C. Pitot, John H. Strickler, John M. Sorensen, L. Leopold, (unknown), David C. Smith	1
6	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer 2011 ·Annals of Oncology ·Guru Sonpavde, В. Б. Матвеев, John M. Burke, J. R. Caton, Mark T. Fleming, Thomas E. Hutson, Matt D. Galsky, William L. Berry, Petr Karlov, Jon Holmlund, Brian Wood, Matthew Brookes, L. Leopold	118
7	Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). 2011 ·Journal of Clinical Oncology ·Gregory R. Pond, Andrew J. Armstrong, Brian Wood, Matthew Brookes, L. Leopold, William R. Berry, Ronald de Wit, Mario A. Eisenberger, I. Tannock, Guru Sonpavde	1
8	A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) 2011 ·Journal of Clinical Oncology ·Guru Sonpavde, В. Б. Матвеев, John M. Burke, J. R. Caton, Mark T. Fleming, Petr Karlov, Jon Holmlund, Brian Wood, Matthew Brookes, L. Leopold	2
9	An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC) 2009 ·Journal of Clinical Oncology ·Gary R. MacVicar, (unknown), James A. Reeves, Janet Maleski, Jon Holmlund, L. Leopold	11
10	An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL) 2009 ·Journal of Clinical Oncology ·Edwin Kingsley, Donald Richards, Lawrence Garbo, Robert H. Gersh, (unknown), L. Leopold, (unknown), (unknown)	10
11	AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development 2009 ·Journal of Clinical Oncology ·Neal Ready, (unknown), (unknown), С. В. Орлов, Alexander Luft, (unknown), (unknown), Jon Holmlund, Brian Wood, L. Leopold	1
12	209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer 2008 ·European Journal of Cancer Supplements ·Gary R. MacVicar, Filippo Greco, James A. Reeves, Brendan D. Curti, Bernard J. Poiesz, Bradley G. Somer, (unknown), L. Leopold	2
13	An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC) 2008 ·Journal of Clinical Oncology ·Gary R. MacVicar, Timothy M. Kuzel, Brendan D. Curti, Bernard J. Poiesz, Bradley G. Somer, F. Anthony Greco, (unknown), (unknown), L. Leopold	17
14	Random aneuploidy in CML patients at diagnosis and under imatinib treatment 2006 ·Cancer Genetics and Cytogenetics ·Aliza Amiel, (unknown), (unknown), L. Leopold, (unknown), Moshe Fejgin, Michael Lishner	9
15	The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia 2006 ·Cancer Genetics and Cytogenetics ·Aliza Amiel, L. Leopold, Naomi Gronich, (unknown), Moshe Fejgin, Michael Lishner	11
16	A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract 2005 ·Journal of Clinical Oncology ·Christian Wülfing, J-P. Machiels, Dick J. Richel, Marc‐Oliver Grimm, Uwe Treiber, Martijn de Groot, Philippe Beuzeboc, John Farrell, Nicole L. Stone, L. Leopold, Iman El‐Hariry	43
17	An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer 2005 ·Journal of Clinical Oncology ·Anthony Fields, David Rinaldi, Charles Henderson, Colin Germond, Luis Chu, (unknown), L. Leopold, M. S. Berger	43
18	Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer 2005 ·Journal of Clinical Oncology ·Helen J. Ross, G. R. Blumenschein, Afshin Dowlati, Joseph Aisner, James R. Rigas, (unknown), L. Leopold	25
19	Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin to patients < 60 years old with untreated acute myeloid leukemia. 2002 ·Blood ·(unknown), Charles A. Schiffer, Richard M. Stone, (unknown), Hugo F. Fernández, Ken Bradstock, Martin S. Tallman, James M. Foran, Gunnar Juliusson, (unknown), Christer Paul, Domenico Russo, Leif Stenke, L. Leopold, David A. Stevenson, Mary Ann Richie, Michael H. Berger	5
20	Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia 2001 ·ORCA Online Research @Cardiff (Cardiff University) ·Daniel J. DeAngelo, Donatella Russo, Sylvie Castaigné, Jordi Esteve, Alan K. Burnett, Anthony P. Goldstone, Martin S. Tallman, Ken Bradstock, Bob Löwenberg, L. Leopold, Mihaela Munteanu, (unknown), Michael H. Berger	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact